P51 REDUCED EFFECTIVENESS OF THE PRIMARY-CARE REGISTRY FOR TARGETED LTBI SCREENING OF HIGH RISK IMMIGRANTS WITH HIV CO-INFECTION

doi:10.1136/thoraxjnl-2012-202678.192

RK Panchal, G Woltmann, P Haldar. *Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom*

Introduction The impact of screening for latent tuberculosis infection (LTBI) in immigrants for tuberculosis (TB) prevention in the UK is dependent on effective strategies for identifying at-risk groups. Here we investigate effectiveness of the primary-care (PC) registry to identify immigrants for enrolment to LTBI screening at the time of GP registration, based on their HIV status.

Methods We performed a 11-year retrospective cohort study of PC registrations, cross-referenced with foreign-born TB (FB-TB) notifications for immigrants entering the UK after 1999 that had HIV testing performed. We assumed LTBI screening to prevent prospective TB would be effective if notifications occurred ≥ 6 months after PC registration. The primary outcome was the proportion of FB-TB preventable with screening at PC registration and compared between subgroups stratified according to HIV status.

Results 624 of 857 FB-TB cases were HIV tested (72.8%) and 84 were HIV seropositive (13.4%). 56 (67%) HIV positive FB-TB cases occurred in immigrants from TB incidence regions 500/100,000. Overall 511 (63%) FB-TB cases were preventable if screened at PC registration. The proportion with unpreventable TB was significantly higher for the HIV positive compared to the HIV negative FB-TB subgroup; [19% vs 10%; RR (95% CI) = 1.89 (1.25 to 2.84), $p=0.003$]. Compared with patients that were HIV negative, time to PC registration after UK entry was longer [median (IQR); 1515 (555–2202) days vs 415 (36–1558) days; $p<0.005$] and time to disease notification shorter [median (IQR); 587 (208–1182) days vs 1163 (669–1854) days, $p<0.005$] for HIV positive FB-TB patients.

Conclusion Targeted LTBI screening at the time of primary-care registration may be a less effective preventative strategy for HIV positive immigrants at highest TB risk. Our data supports the need to promote early registration and extended screening to include HIV and other blood-borne viruses as part of an integrated immigrant screening programme.

P52 THE USE OF MAGNETIC RESONANCE STUDIES [MR] IN ASSESSING RESPONSE AND GUIDING DURATION OF TREATMENT IN SPINAL TUBERCULOSIS

doi:10.1136/thoraxjnl-2012-202678.193

KA Chengappa, J Lucas, HJ Milburn. *Guy's and St. Thomas' NHS Foundation Trust, London, UK*

Background Significant delays still occur in the diagnosis of spinal tuberculosis [sTB] and there is little consensus on the follow-up and duration of treatment. Current UK and international guidelines for sTB still recommend standard short course chemotherapy but this does not reflect clinical practise.

Aims and methods We performed a retrospective study at a UK teaching hospital to identify the demographic and clinical features of our sTB population and the value of spinal magnetic resonance studies [MR] in guiding response to and duration of treatment. Results Data was available for 26 patients [2005–2011] with an average age of 40 years [60% male]. Mean time to diagnosis was 9.3 months. At presentation the commonest symptoms were back pain – 26/26, constitutional symptoms [fevers, sweats, weight loss] – 12/26 and neurological symptoms – 12/26. In 13/26 [50%], the diagnosis was made following an emergency admission. Positive microbiology was obtained in 19/26 and 84% of these were fully sensitive organisms. 42% had disease at multiple spinal levels and 73% had associated paraspinal abscesses. At 6 months only 2/26 [7%] had MR evidence of resolution of active disease and 11/26 [42%] had persisting symptoms

[back pain and neurological symptoms]. The median number of follow-up scans/patient was 2 and mean duration of treatment was 10.7 months. Of the 24 patients who received >6 months treatment, 5 [20%] still had symptoms after completion [back pain].

Conclusions MR provides a useful means of assessing response to treatment and can help in deciding duration of treatment. However the frequency/intervals at which scans should be done is not clear.

P53 FAST TRACK TB RADIOLOGY: A BIT OF A BONSAI OR A TREE IN BUD?

doi:10.1136/thoraxjnl-2012-202678.194

GS Bhat, F Oyesanya, J Cleverley, C Cash, J Goldring, I Cropley, MCI Lipman Royal. *Free Hospital, London, London*

Background Prompt diagnosis is central to effective tuberculosis (TB) management. To minimise clinician related delay, we developed a pathway where imaging suggestive of active TB is flagged for review by specialist radiologists and the TB service at a weekly meeting. If required, the patient is then fast-tracked for clinical assessment by the TB team.

Methods Prospective study of patients referred to our radiology service June 2011–February 2012 with imaging flagged as suspicious of TB. Case management, diagnosis and final outcome were recorded.

Results 68 subjects, median age 45 years (range 1–91), were studied. Of the flagged images, 38 were chest radiographs, 28 CT chest +/- abdomen, 1 CT head and 1 MRI spine. 32 (47%) were reported to be highly suspicious for TB. The remaining 36 (53%) had changes such as apical scarring, pleural effusion and/or mediastinal lymphadenopathy where TB was part of the differential diagnosis. 19 (28%) of the radiological referrals were from Primary Care & 12 (18%) Accident & Emergency (A & E). 59 of 68 (87%) were seen in a TB clinic at a median time from date of imaging to appointment of 13 days (range 1–100). 18 (31%) had a final diagnosis of active TB. 3 were already on TB treatment, and the remaining 15 started a median 24 days from the time of imaging. Apart from TB, common final diagnoses included bacterial or NTM infection, bronchiectasis and sarcoidosis. 4/19 (21%) of GP and 3/12 (25%) A & E referrals had active TB. Patients not seen in a TB clinic were referred to other clinical services (4 cases – all with significant pathology) or no action taken following specialist review of their imaging (5).

Conclusion The fast track service has a high yield for TB and other significant pathologies. Almost half of the reviews arose following Primary Care or A & E imaging. Prompt specialist imaging review is associated with rapid and appropriate triage to TB and other services. Further work will compare this approach to standard care pathways.

P54 TESTING FOR BLOOD BORNE VIRUSES IN A TB CLINIC: WHY DISCRIMINATE ON THE BASIS OF WHO GETS TB TREATMENT?

doi:10.1136/thoraxjnl-2012-202678.195

¹TP Cusack, ²J Sewell, ¹S Chaytor, ¹J Johnson, ¹A Solamalai, ¹P MacKenzie, ¹A Goodburn, ¹S Hopkins, ¹I Cropley, ¹M Lipman. *Royal Free London NHS Foundation Trust, London, United Kingdom; ²University College London, London, United Kingdom*

Introduction Testing for blood borne viruses (BBV), in particular HIV, is a standard of care for people on active tuberculosis (TB) treatment. Although individuals with latent TB infection and those with suspected TB disease are drawn from similar populations, with presumably similar risks for BBV, there are little reported data on this. Our TB clinic has a policy of routine testing for HIV, Hepatitis B (HBV) & Hepatitis C (HCV) on those with a diagnosis of active and latent TB. Here we review our data.

Methods Information on all adults attending TB services between 01/01/2009 and 19/07/2012 at our centre (apart from those known to be HIV infected at the time of TB service encounter) were extracted from hospital clinical and pathology information systems.

Results 1656 subjects were seen (Active TB: 22%, Latent TB: 11%, Other final diagnosis not TB: 67%). 748 (45%) had all three BBV tests performed. This was significantly different between the groups, as subjects with either latent or active TB were more likely to have all three tests (Active: 90%, Latent: 83% vs Other diagnosis: 24%, $P < 0.001$). In those tested, an HIV positive result was more frequently found in active TB (7.5%), whilst the HIV prevalence was similar in the two other groups (Latent 1.3% vs Other 1.4%). HBV was more common in Active & Latent TB populations compared to the Others (3% vs 0.8%, $P < 0.001$). HCV had a similar prevalence pattern to HIV, in that it was more common in those with Active TB (3% vs Latent TB: 0.6%, Other 1%, $P = 0.06$).

Conclusion We find a high rate of uptake for HIV, HBV & HCV testing in our subjects treated for active and latent TB. HIV & HCV were more common in the former population. Adults with latent TB had a similar prevalence of HIV and HCV to those subjects whose final diagnosis was other than TB. However, the latter had a much lower overall uptake of BBV testing. This is of concern and suggests that we are missing opportunities to diagnose unsuspected BBV infection in a large number of clinic attendees.

P55 IDENTIFYING POTENTIAL PREDICTORS OF MORTALITY AND MORBIDITY IN TUBERCULOUS MENINGITIS (TBM)

doi:10.1136/thoraxjnl-2012-202678.196

C Petridou, C Petridou, A Jayaratnam. *Barking, Havering Redbridge, NHS Trust, Ilford, United Kingdom*

Introduction The early and prompt diagnosis of TBM is essential to improve outcomes. Delayed treatment leads to increased morbidity and mortality. Cerebrospinal fluid (CSF) findings may assist in early diagnosis as well as potentially identifying patients at high-risk of death.

Methods A retrospective analysis of patients treated for TBM from 2000–2010 was undertaken using the London TB Register. Data was collected from medical records and pathology results.

Results Mortality was 20% (8/41) and 12% (5/41) were left with permanent neurological deficits. *Mycobacterium tuberculosis* (MTB) was cultured from CSF in 37% (14/38). Mortality in patients in whom CSF was culture positive was higher than those whose CSF culture was negative (33% vs 16%). The mean value of CSF protein was higher in patients with poorer outcomes than those who recovered fully (2.72 vs 1.92 g/L).

Corticosteroids were given to 92% of patients (35/38). Of the three patients who did not receive steroids, one was left with a permanent disability.

Conclusions In our population, we observed high mortality and morbidity rates for patients diagnosed with TBM. A large proportion of diagnoses were not confirmed microbiologically. Higher mortality rates were observed in those whose CSF cultured MTB. A possible explanation for this finding is that those patients for whom microbiological confirmation was not obtained, the presumptive diagnosis of TBM was not correct. There is a trend towards higher mortality and morbidity in those with higher CSF protein values. This may be an indicator of increased bacterial load with an associated increase in inflammatory cytokines.

P56 USE OF THE TUBERCULIN SKIN TEST AND TSPOT FOR SCREENING PRIOR TO TNF ANTAGONIST THERAPY IDENTIFIES ADDITIONAL PATIENTS ELIGIBLE FOR CHEMOPROPHYLAXIS COMPARED TO USE OF RISK ASSESSMENT STRATEGIES ALONE

doi:10.1136/thoraxjnl-2012-202678.197

K Manalan, A Singanayagam, PL Molyneux, PM George, DW Connell, A Lalvani, M Wickremasinghe, OM Kon. *St. Mary's Hospital, London, UK*

Patients with rheumatological disease who are treated with TNF antagonist therapy are at increased risk of reactivating latent tuberculosis infection (LTBI). It is believed that immunosuppressant therapy in this group may reduce the reliability of the tuberculin skin test (TST) due to a high incidence of anergy. The value of interferon gamma release assays in this setting is also unclear. The aim of this study was to assess the value of a combination of the TST and *Tspot* for screening in patients on immunosuppressants and compare to the BTS-recommended approach, which advocates treatment decisions based on risk stratification.

Methods Adult patients referred for TB screening to a tertiary centre prior to commencement of Anti-TNF therapy were included in the study. All patients received a uniform screening protocol of clinical history, chest radiograph, stratification of TB risk (by ethnicity and age according to BTS guideline risk-tables), TST and *Tspot*.

Results There were 137 patients included with 116 (84.7%) taking immunosuppressant medication at the time of screening. Of the sub-group on immunosuppressants, 17 patients (14.7%) had positive TST results (5 patients with result > 15 mm in presence of BCG, 12 patients with result > 5 mm in absence of previous BCG). Of this sub-group with positive TST results, 12 patients (70.6%) would not have been treated according to risk-stratification tables. Of the sub-group on immunosuppressants, 25 patients (21.6%) had positive *Tspot* results and 1 patient had an indeterminate result.

Of this subgroup with positive *Tspot* results, 17 patients (68%) would not have been treated according to risk-stratification tables.

When comparing strategies, use of risk-stratification tables alone would lead to 26 patients being treated with chemoprophylaxis. Addition of either positive TST and/or positive *Tspot* in patients not identified by risk stratification method led to an additional 22 patients eligible for treatment (9 patients *Tspot* positive alone; 7 patients TST positive alone; 6 patients double positive).

Conclusion Performing both a TST and *Tspot* in patients on immunosuppressants prior to commencement of Anti-TNF screening gives an additional yield of potential LTBI when risk assessment strategies alone would not have identified these.

P57 COMPARATIVE COST-EFFECTIVENESS OF IGRA TO DETECT LATENT TB INFECTION IN UK INFLAMMATORY BOWEL DISEASE PATIENTS INITIATING ANTI-TNF α AGENTS

doi:10.1136/thoraxjnl-2012-202678.198

¹K Greveson, ¹S Capocci, ¹S Murthy, ¹C Smith, ¹S Morris, ²C Murray, ³I Copley, ²M Hamilton, ¹M Lipman. ¹Department of Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK; ²Centre for Gastroenterology, Royal Free London NHS Foundation Trust, London, UK; ³Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK

Introduction Two commercial Interferon Gamma release assays (IGRA) are approved in the UK by NICE to detect *M tuberculosis* (Mtb) infection. They use different test platforms. Both may provide borderline (neither clear positive or negative) or indeterminate (failure of control samples) results, especially in people taking immunomodulatory therapy. Since 2008, we have applied a standard IGRA-based assessment for latent Mtb infection in inflammatory bowel disease (IBD) patients being considered for anti-TNF α therapy. Initially this involved T-Spot.TB (TSTB) but in December 2010, our service switched to Quantiferon Gold In-tube (QFGIT). Here we review the performance and cost-effectiveness of these assays within our protocol.

Method Adult IBD patients were assessed using symptom review, chest radiograph (CXR) and IGRA Indeterminate/borderline IGRA were repeated and patients with persistently indeterminate/borderline results plus TB risk factors, or a positive result were referred to TB services. Cost per patient assessment used the average of assay costs and repeated assays plus onward referrals for those with indeterminate/borderline results. Appointment costs were taken from